Stern Adam K reported grant involving 28,000 shares of DarioHealth Corp. at $0.00 for $0 on Sep 24, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Sep 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
28,000Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
57,717Direct
Trade date
Sep 24, 2026Grant
Filed
Sep 28, 2026, 4:07 PM ET4-day reporting delay
Accession
0001104659-26-111351Code A · Transaction 230336
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 18, 2025Conversion11,760$40.40$475,104Trade 230334
Sep 18, 2025Conversion8,435$16.60$140,021Trade 230335
Sep 18, 2025Conversion250$1,000.00−$250,000Trade 230337
Sep 18, 2025Conversion100$1,000.00−$100,000Trade 230338
5 transaction rows in this filing. Joint filers share the same rows.

DRIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
DRIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Oct 5, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Pursuant to the Second Amended and Restated Certificates of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock and the Series D-2 Preferred Stock filed with the Secretary of State of the State of Delaware, the mandatory conversion period of all outstanding shares of each such series was accelerated, and such shares automatically converted into shares of Common Stock effective September 18, 2025, together with all accrued and unpaid dividends, including dividend shares, subject to certain beneficial ownership limitations. F2: AKS Family Partners L.P.'s 250 shares of Series C Preferred Stock automatically converted into 6,189 shares of Common Stock on September 18, 2025, at a conversion price of $40.40 per share. AKS Family Partners L.P. also received 5,571 shares of Common Stock in respect of accrued and unpaid dividends on the Series C Preferred Stock, for a total of 11,760 shares of Common Stock. The conversion occurred after the 20-for-1 reverse stock split effected on August 28, 2025, and all share amounts and prices are reported on a post-split basis. The Series C Preferred Stock was previously reported on the Reporting Person's Form 4 filed in September 2025 as 123,763 shares on a pre-split, as-converted basis. F3: AKS Family Partners L.P.'s 100 shares of Series D-2 Preferred Stock automatically converted into 6,025 shares of Common Stock on September 18, 2025, at a conversion price of $16.60 per share. AKS Family Partners L.P. also received 2,410 shares of Common Stock in respect of accrued and unpaid dividends on the Series D-2 Preferred Stock, for a total of 8,435 shares of Common Stock. F4: The restricted share award shall vest on the last day of the second-year anniversary after the grant date.